Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
PLx Pharma National Institutes of Health (NIH) Texas Higher Education Coordinating Board |
---|---|
Information provided by: | PLx Pharma |
ClinicalTrials.gov Identifier: | NCT00219700 |
To determine the safety and efficacy of 3 x 800 mg/day IBU-PC assessed by endoscopy and incidence of adverse events
Condition | Intervention | Phase |
---|---|---|
Osteoarthritis |
Drug: Ibuprofen-PC |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Phase II, Randomized, Blinded Study of Ibuprofen-PC and Ibuprofen in Patients With Osteoarthritis to Investigate Efficacy and Gastrointestinal Toxicity |
Estimated Enrollment: | 125 |
Study Start Date: | January 2005 |
Study Completion Date: | November 2005 |
Primary Completion Date: | November 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | PLx Pharma ( Ron Zimmerman/President ) |
Study ID Numbers: | PL-IB-002 |
Study First Received: | September 20, 2005 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00219700 |
Health Authority: | United States: Food and Drug Administration |
NSAID-PC IBU-PC |
Ibuprofen Musculoskeletal Diseases Osteoarthritis |
Joint Diseases Arthritis Rheumatic Diseases |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cyclooxygenase Inhibitors Enzyme Inhibitors Pharmacologic Actions Analgesics, Non-Narcotic |
Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |